Therapeutic potential of natural product signal transduction agents

Current Opinion in Biotechnology

Volumn 17, Issue 6, 2006, Pages 631-637

  Koehn, Frank E ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; ENZYME IMMOBILIZATION; IMMUNOLOGY; MICROORGANISMS;

DRUG DISCOVERY; SIGNAL TRANSDUCTION AGENTS; THERAPEUTIC AGENTS;

DRUG THERAPY;

AP 23576; ASCOMYCIN; EVEROLIMUS; FK 506 BINDING PROTEIN; IMMUNOPHILIN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; LACTAM DERIVATIVE; NORMERIDAMYCIN; POLYKETIDE; PROTEASOME; RAPAMYCIN; SALINOSPORAMIDE; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; TSUKUBAENOLIDE; UBIQUITIN; UNCLASSIFIED DRUG;

BIOSYNTHESIS; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EXCRETION; DRUG ISOLATION; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC ENGINEERING; GENETIC MANIPULATION; HEART FAILURE; IC 50; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT STRAIN; RENAL DIABETES; REVIEW; SIGNAL TRANSDUCTION; STREPTOMYCES HYGROSCOPICUS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BIOLOGICAL PRODUCTS; DRUG DESIGN; IMMUNOPHILINS; PHARMACEUTICAL PREPARATIONS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION;

EID: 33751226567     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2006.09.006     Document Type: Review

References (53)

1. Kane S.E. Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents 16 (2006) 147-164
2. Miller B.S., and Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 65 (2005) 10123-10127
3. Haura E.B., Turkson J., and Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2 (2005) 315-324
4. Tas S.W., Remans P.H.J., Reedquist K.A., and Tak P.P. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr Pharm Des 11 (2005) 581-611
5. Wheeler-Jones C.P.D. Cell signaling in the cardiovascular system: an overview. Heart 91 (2005) 1366-1374
6. Shimokawa H., and Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25 (2005) 1767-1775
7. Zhang K.Y.J., Ibrahim P.N., Gillette S., and Bollag G. Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets 9 (2005) 1283-1305
8. Wrigley S.K., Kau D.A., Waters B., and Davies J.E. Signal transduction inhibitors from microorganisms. Special Publication - Royal Society of Chemistry 257 (2000) 86-99
9. Koch M.A., Wittenberg L.-O., Basu S., Jeyaraj D.A., Gourzoulidou E., Reinecke K., Odermatt A., and Waldmann H. Compound library development guided by protein structure similarity clustering and natural product structure. Proc Natl Acad Sci USA 101 (2004) 16721-16726. A conceptual rationale for the high hit rates of natural product structures against multiple protein targets, and a demonstration of the principle of privileged natural product structures in library design.
10. Koehn F.E., and Carter G.T. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4 (2005) 206-220. A review describing the history, challenges and enabling technologies in natural product based drug discovery.
11. Wang J., Soisson S.M., Young K., Shoop W., Kodali S., Galgoci A., Painter R., Parthasarathy G., Tang Y.S., Cummings R., et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441 (2006) 358-361. Strong example of a new structural class of natural product with a unique mechanism of action discovered by high-throughput screening.
12. Rybak M.J. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect 12 (2006) 24-32
13. Camardo J. The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Transplant Proc 35 (2003) 18S-24S
14. Arkin M.R., and Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3 (2004) 301-317
15. Lawrence J.C., Lin T.A., McMahon L.P., and Choi K.M. Modulation of the protein kinase activity of mTOR. Curr Top Microbiol Immunol 279 (2004) 199-213
16. 2+/calmodulin-dependent protein phosphatase in diverse eukaryotes. Topics in Current Genetics 5 (2004) 73-90
17. Pemberton T.J., and Kay J.E. Identification and comparative analysis of the peptidyl-prolyl cis/trans isomerase repertoires of H. sapiens, D. melanogaster, C. elegans, S. cerevisiae and Sz. pombe. Comp Funct Genomics 6 (2005) 277-300
18. Wullschleger S., Loewith R., and Hall Michael N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484. A thorough review of the multiple, intricate cellular functions of the TOR signalling pathway.
19. Witzig T.E., Geyer S.M., Ghobrial I., Inwards D.J., Fonseca R., Kurtin P., Ansell S.M., Luyun R., Flynn P.J., Morton R.F., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23 (2005) 5347-5356
20. Vignot S., Faivre S., Aguirre D., and Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann oncol 16 (2005) 525-537
21. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17 (2006) 487-494
22. Martin Dietmar E., and Hall Michael N. The expanding TOR signaling network. Curr Opin Cell Biol 17 (2005) 158-166
23. Garcia-Touchard A., Burke Sandra E., Toner John L., Cromack K., and Schwartz Robert S. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 27 (2006) 988-993
24. Sharma S., Ying J., Razeghi P., Stepkowski S., and Taegtmeyer H. Atrophic remodeling of the transplanted rat heart. Cardiology 105 (2006) 128-136
25. Lloberas N., Cruzado J.M., Franquesa M., Herrero-Fresneda I., Torras J., Alperovich G., Rama I., Vidal A., and Grinyo J.M. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 17 (2006) 1395-1404
26. Lee V.W.S., and Chapman J.R. Sirolimus: its role in nephrology. Nephrology 10 (2005) 606-614
27. Pong K., and Zaleska M.M. Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Target CNS Neurol Disord 2 (2003) 349-356
28. Babine R.E., Villafranca J.E., and Gold B.G. FKBP immunophilin patents for neurological disorders. Expert Opinion on Therapeutic Patents 15 (2005) 555-573
29. Summers M.Y., Leighton M., Liu D., Pong K., and Graziani E.I. 3-Normeridamycin: a potent non-immunosuppressive immunophilin ligand is neuroprotective in dopaminergic neurons. J Antibiot (Tokyo) 59 (2006) 184-189. A solid example of the isolation, structure elucidation and biological activity of a neuroprotective immunophilin ligand.
30. Yano M., Yamamoto T., Ikemoto N., and Matsuzaki M. Abnormal ryanodine receptor function in heart failure. Pharmacol Ther 107 (2005) 377-391
31. Wehrens X.H.T., and Marks A.R. Mechanisms of heart failure: emerging molecular targets. Drug Discov Today: Disease Mechanisms 1 (2004) 9-16
32. Graziani E.I., Ritacco F.V., Summers M.Y., Zabriskie T.M., Yu K., Bernan V.S., Greenstein M., and Carter G.T. Novel sulfur-containing rapamycin analogs prepared by precursor-directed biosynthesis. Org Lett 5 (2003) 2385-2388
33. Weist S., and Suessmuth R.D. Mutational biosynthesis: a tool for the generation of structural diversity in the biosynthesis of antibiotics. Appl Microbiol Biotechnol 68 (2005) 141-150
34. Weissman K.J., and Leadlay P.F. Combinatorial biosynthesis of reduced polyketides. Nat Rev Microbiol 3 (2005) 925-936. A thorough review of the principles, strategies and technical challenges involved in the genetic manipulation of natural product biosynthetic gene clusters to produce new molecules.
35. Ansell S.M., Geyer S.M., Kurtin P.J., Rowland K.M., Flynn P.J., Morton R.F., Dakhil S.R., Gross H.M., Maurer M.J., Kaufmann S.H., et al. Anti-tumor activity of CCI-779 in relapsed mantle cell lymphoma. Haematologica Reports 1 (2005) 92-94
36. Gregory M.A., Petkovic H., Lill R.E., Moss S.J., Wilkinson B., Gaisser S., Leadlay P.F., and Sheridan R.M. Mutasynthesis of rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis. Angew Chem Int Ed Engl 44 (2005) 4757-4760
37. Menzella H.G., Reid R., Carney J.R., Chandran S.S., Reisinger S.J., Patel K.G., Hopwood D.A., and Santi D.V. Combinatorial polyketide biosynthesis by de novo design and rearrangement of modular polyketide synthase genes. Nat Biotechnol 23 (2005) 1171-1176. This paper describes the multiple recombination of gene modules from eight different polyketide synthase clusters and their expression in Escherichia coli to produce new molecules.
38. Wenzel S.C., and Mueller R. Recent developments towards the heterologous expression of complex bacterial natural product biosynthetic pathways. Curr Opin Biotechnol 16 (2005) 594-606
39. Hutchinson C.R. Manipulating microbial metabolites for drug discovery and production. Natural Products (2005) 77-93
40. Voorhees P.M., and Orlowski R.Z. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46 (2006) 189-213
41. Richardson P.G., Mitsiades C., Hideshima T., and Anderson K.C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57 (2006) 33-47
42. Tsukamoto S., and Yokosawa H. Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development. Curr Med Chem 13 (2006) 745-754
43. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., and Fenical W. salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed Engl 42 (2003) 355-357
44. Corey E.J., and Li W.-D. Total synthesis and biological activity of lactacystin, omuralide and analogs. Chem Pharm Bull (Tokyo) 47 (1999) 1-10
45. Groll M., Huber R., and Potts B.C.M. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 128 (2006) 5136-5141. An insightful X-ray study and discussion showing the unique structural characteristics involved in an elegantly potent natural product inhibitor. The work fully illustrates how nature optimizes natural product structures.
46. Reddy L.R., Fournier J.-F., Reddy B.V.S., and Corey E.J. An efficient, stereocontrolled synthesis of a potent omuralide-salinosporin hybrid for selective proteasome inhibition. J Am Chem Soc 127 (2005) 8974-8976
47. Hogan P.C., and Corey E.J. Proteasome inhibition by a totally synthetic β-lactam related to salinosporamide A and omuralide. J Am Chem Soc 127 (2005) 15386-15387
48. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8 (2005) 407-419
49. Williams P.G., Buchanan G.O., Feling R.H., Kauffman C.A., Jensen P.R., and Fenical W. New cytotoxic salinosporamides from the marine actinomycete Salinispora tropica. J Org Chem 70 (2005) 6196-6203
50. Keller M., and Zengler K. Tapping into microbial biodiversity. Nat Rev Microbiol 2 (2004) 141-150
51. Demain A. From natural products discovery to commercialization: a success story. Int Microbiol Biotechnol 33 (2006) 486-495
52. Bode H.B., and Muller R. The impact of bacterial genomics on natural product research. Angew Chem Int Ed Engl 44 (2006) 6828-6846
53. Lau J., Frykman S., Regentin R., Ou S., Tsuruta H., and Licari P. Optimizing the heterologous production of epothilone D in Myxococcus xanthus. Biotechnol Bioeng 78 (2002) 280-288